BeyondSpring (BYSI) Other Non-Current Liabilities (2020 - 2026)
BeyondSpring (BYSI) posted Other Non-Current Liabilities of $4.2 million for Q1 2026, up 6.48% sequentially from $4.0 million in Q4 2025, and up 14.38% YoY from $3.7 million in Q1 2025.
BeyondSpring (BYSI) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
BeyondSpring has reported Other Non-Current Liabilities for 7 years, with the latest figure at $4.2 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 14.38% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 million (up 14.38% YoY) and the FY2025 annual result came in at $4.0 million, up 8.0% from the prior year.
- Other Non-Current Liabilities improved to $4.2 million in Q1 2026 per BYSI's latest filing, from $4.0 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $4.2 million in Q1 2026 and troughed at $692000.0 in Q2 2022.
- A 5-year average of $3.5 million and a median of $3.7 million in 2023 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Liabilities jumped 416.36% in 2022, then slipped 0.51% in 2024.
- Over 5 years, Other Non-Current Liabilities stood at $3.7 million in 2022, then increased by 1.2% to $3.7 million in 2023, then retreated by 0.51% to $3.7 million in 2024, then increased by 8.0% to $4.0 million in 2025, then rose by 6.48% to $4.2 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $4.2 million, $4.0 million, and $3.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.20 Bn | 131.35 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.09 Bn | 78.10 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.04 Bn | 9.65 Bn | 668.28 Mn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.50 Bn | - |
| 10 | BeyondSpring | 29.77 Mn | 29.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.42 Mn |
| Mar 31, 2026 | 4.24 Mn |
| Dec 31, 2025 | 3.98 Mn |
| Sep 30, 2025 | 3.84 Mn |
| Jun 30, 2025 | 3.78 Mn |
| Mar 31, 2025 | 3.71 Mn |
| Dec 31, 2024 | 3.69 Mn |
| Jun 30, 2024 | 3.61 Mn |
| Dec 31, 2023 | 3.71 Mn |
| Jun 30, 2023 | 3.53 Mn |
| Dec 31, 2022 | 3.66 Mn |
| Jun 30, 2022 | 692,000.00 |
| Dec 31, 2021 | 709,000.00 |
| Sep 30, 2021 | 1.26 Mn |
| Jun 30, 2021 | 341,000.00 |
| Mar 31, 2021 | 278,000.00 |
| Dec 31, 2020 | 278.00 |